Clinical Trials Logo

Filter by:
NCT ID: NCT02449473 Completed - Asthma Clinical Trials

Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids

MESOS
Start date: September 29, 2015
Phase: Phase 2
Study type: Interventional

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid.

NCT ID: NCT02449239 Completed - Bladder Cancer Clinical Trials

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

VISTA
Start date: August 2015
Phase: Phase 3
Study type: Interventional

Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy

NCT ID: NCT02447718 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Vaccinating Children After Chemotherapy

Start date: November 16, 2015
Phase: Phase 4
Study type: Interventional

This multi-center open label clinical trial aims to identify predictors of low antibody titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6 months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and 13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months post-chemotherapy, followed by 23-valent pneumococcal polysaccharide vaccination (PPV23) 2 months later. The results will support the development of clinical practice guidelines for this population.

NCT ID: NCT02447692 Completed - Clinical trials for Acute Respiratory Failure

Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study

PROMIZING
Start date: September 14, 2016
Phase: N/A
Study type: Interventional

For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?

NCT ID: NCT02447471 Completed - Clinical trials for Blood Pressure Measurement

Agreement of the Nexfin™ Monitor With Non-invasive Blood Pressure Measurement

Nexfin Pilot
Start date: May 2015
Phase: N/A
Study type: Observational

Currently, BP is measured using an inflatable cuff wrapped around the patient's upper arm. This can be set to inflate every minute, but measurement may fail due to patient movement or shivering. Failed measurement occurs in up to 38% of patients. This study aims to determine how the Nexfin device - which measures BP using a cuff wrapped around a finger - compares to standard BP measurement.

NCT ID: NCT02447302 Completed - Ulcerative Colitis Clinical Trials

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Start date: October 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.

NCT ID: NCT02446899 Completed - Clinical trials for Active Systemic Lupus Erythematosus

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Start date: July 9, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

NCT ID: NCT02446743 Completed - Clinical trials for Infections, Meningococcal

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Start date: November 17, 2015
Phase: Phase 3
Study type: Interventional

The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents [who previously participated in parent studies V72_41 (NCT0142384) and V72P10 (NCT00661713)] and 2) the kinetics of immune response following booster vaccination with rMenB+OMV NZ

NCT ID: NCT02446613 Completed - Asthma and Rhinitis Clinical Trials

Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958

Start date: June 22, 2015
Phase: Phase 2
Study type: Interventional

This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958. This is a single centre, single period study in subjects with respiratory allergy/allergies who completed the study TL7116958 in 2014 to investigate the long term effect of previous treatment with GSK2245035 compared with placebo on total nasal symptoms elicited by nasal allergen challenge. Subjects and staff will remain blinded to the treatment received in the TL7116958 study (GSK2245035 or placebo). The study will consist of a screening visit to assess eligibility criteria, a study period consisting of a single visit when the nasal allergen challenge will be performed, and follow up by phone or a clinic visit at the discretion of the investigator 4-7 days following the allergen challenge. Eligible subjects will participate in this study for approximately70 days total from screening to follow up.

NCT ID: NCT02445248 Completed - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

JULIET
Start date: July 29, 2015
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.